ECSP024358A - Nuevas fomas solidas de la meso´rogestina 11beta(4e-hidroxiiminometil)-fenil) 17 alfa-metoximetil-17 beta-metoxi-estra-4,9 -dien-3-ona - Google Patents

Nuevas fomas solidas de la meso´rogestina 11beta(4e-hidroxiiminometil)-fenil) 17 alfa-metoximetil-17 beta-metoxi-estra-4,9 -dien-3-ona

Info

Publication number
ECSP024358A
ECSP024358A EC2002004358A ECSP024358A ECSP024358A EC SP024358 A ECSP024358 A EC SP024358A EC 2002004358 A EC2002004358 A EC 2002004358A EC SP024358 A ECSP024358 A EC SP024358A EC SP024358 A ECSP024358 A EC SP024358A
Authority
EC
Ecuador
Prior art keywords
11beta
estra
rogestina
hidroxiiminometil
metoximetil
Prior art date
Application number
EC2002004358A
Other languages
English (en)
Inventor
Detlef Grawe
Peter Hoesel
Uwe Mueller
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of ECSP024358A publication Critical patent/ECSP024358A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

El invento se refiere a las nuevas formas sólidas de la mesoprogestina 11Beta-(4e(hidroxiiminometil)-fenil)-17a-metoximetil-17B-metoxi-estra-4,9-dien-30na (ixima J 867), especialmente a una forma extrapura y estable, amorfa o extracistalina (forma no solvatada (no solvato)/no hidrato), del compuesto J 867, a un método para su preparación y a su uso en composiciones farmacéutircas. La nuevas formas sólidas se caracterizan especialmente por su alta estabilidad. Estas formas sólidas de la oxima J867 pueden utilizarse especialmente en el control de la fertilidad y en la terapia de reemplazo hormonal.
EC2002004358A 2000-05-23 2002-11-22 Nuevas fomas solidas de la meso´rogestina 11beta(4e-hidroxiiminometil)-fenil) 17 alfa-metoximetil-17 beta-metoxi-estra-4,9 -dien-3-ona ECSP024358A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00110887A EP1157996A1 (de) 2000-05-23 2000-05-23 Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on

Publications (1)

Publication Number Publication Date
ECSP024358A true ECSP024358A (es) 2003-03-31

Family

ID=8168805

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2002004358A ECSP024358A (es) 2000-05-23 2002-11-22 Nuevas fomas solidas de la meso´rogestina 11beta(4e-hidroxiiminometil)-fenil) 17 alfa-metoximetil-17 beta-metoxi-estra-4,9 -dien-3-ona
EC2008004358A ECSP084358A (es) 2000-05-23 2008-10-22 NUEVAS FORMAS SÓLIDAS DE LA MESOPROGESTINA 11ß-[4E-(HIDROXIIMINOMETIL)-FENIL]- 17ALFA-METOXIMETIL-17ß-METOXI-ESTRA-4,9-DIEN-3-ONA

Family Applications After (1)

Application Number Title Priority Date Filing Date
EC2008004358A ECSP084358A (es) 2000-05-23 2008-10-22 NUEVAS FORMAS SÓLIDAS DE LA MESOPROGESTINA 11ß-[4E-(HIDROXIIMINOMETIL)-FENIL]- 17ALFA-METOXIMETIL-17ß-METOXI-ESTRA-4,9-DIEN-3-ONA

Country Status (30)

Country Link
US (1) US7799770B2 (es)
EP (3) EP1157996A1 (es)
JP (1) JP2003534350A (es)
KR (1) KR100553292B1 (es)
CN (1) CN100384867C (es)
AT (1) ATE397617T1 (es)
AU (2) AU2001256344B2 (es)
BG (1) BG65968B1 (es)
BR (1) BR0111058A (es)
CA (1) CA2409869C (es)
CZ (1) CZ2003620A3 (es)
DE (1) DE50114012D1 (es)
DK (1) DK1292607T3 (es)
EA (1) EA005623B1 (es)
EC (2) ECSP024358A (es)
ES (1) ES2307613T3 (es)
HR (2) HRP20021032B1 (es)
HU (1) HUP0301956A3 (es)
IL (2) IL152868A0 (es)
ME (1) MEP15608A (es)
MX (1) MXPA02011524A (es)
NO (1) NO327004B1 (es)
NZ (1) NZ522768A (es)
PL (1) PL358789A1 (es)
PT (1) PT1292607E (es)
RS (1) RS50493B (es)
SK (1) SK2922003A3 (es)
UA (1) UA73988C2 (es)
WO (1) WO2001090137A2 (es)
ZA (1) ZA200209322B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
TW200640450A (en) * 2005-01-18 2006-12-01 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Amorphous and crystalline forms of dorzolamide hydrochloride and processes of making same
DE102006018888A1 (de) * 2006-04-18 2007-10-25 Bayer Schering Pharma Ag Verfahren zur Herstellung von 4-[17beta-Methoxy-17alpha-methoxymethyl-3-oxoestra-4,9-dien-11beta-yl]benzaldehyd-(E)-oxims (Asoprisnil)
US20090054387A1 (en) 2006-04-18 2009-02-26 Detlef Grawe Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxestra-4,9-dien-11beta-yl]benzaldehyde (E)-oxime (asoprisnil)
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19610667C2 (de) * 1996-03-08 1998-04-09 Schering Ag (Z)-11ß-[4-(Dimethylamino)phenyl]17ß-hydroxy-17alpha-(3-hydroxy-1-propenyl)estr-4-en-3-on als kristallines Ansolvat
WO2001009116A2 (en) * 1999-07-29 2001-02-08 Eli Lilly And Company A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE

Also Published As

Publication number Publication date
CN100384867C (zh) 2008-04-30
ATE397617T1 (de) 2008-06-15
WO2001090137A2 (de) 2001-11-29
UA73988C2 (en) 2005-10-17
HRP20080423A2 (en) 2008-10-31
DK1292607T3 (da) 2008-10-13
WO2001090137A3 (de) 2002-04-04
EP1862469A2 (de) 2007-12-05
EA200201192A1 (ru) 2003-06-26
HRP20021032B1 (hr) 2008-09-30
RS50493B (sr) 2010-03-02
CA2409869A1 (en) 2002-11-20
AU2001256344B8 (en) 2001-12-03
BR0111058A (pt) 2003-04-15
AU2001256344B2 (en) 2007-01-25
BG107557A (bg) 2004-01-30
NZ522768A (en) 2005-03-24
CN1430624A (zh) 2003-07-16
CZ2003620A3 (cs) 2003-08-13
ES2307613T3 (es) 2008-12-01
ZA200209322B (en) 2005-03-10
EP1292607B1 (de) 2008-06-04
EP1157996A1 (de) 2001-11-28
AU5634401A (en) 2001-12-03
HUP0301956A3 (en) 2010-03-29
SK2922003A3 (en) 2003-08-05
HUP0301956A2 (hu) 2003-09-29
KR100553292B1 (ko) 2006-02-22
HRP20021032A2 (en) 2005-02-28
EP1292607A2 (de) 2003-03-19
PL358789A1 (en) 2004-08-23
PT1292607E (pt) 2008-09-15
MEP15608A (en) 2010-06-10
KR20030028742A (ko) 2003-04-10
YU88702A (sh) 2006-01-16
NO20025613D0 (no) 2002-11-22
IL152868A0 (en) 2003-06-24
NO327004B1 (no) 2009-04-06
NO20025613L (no) 2002-11-22
ECSP084358A (es) 2008-11-27
DE50114012D1 (en) 2008-07-17
JP2003534350A (ja) 2003-11-18
US7799770B2 (en) 2010-09-21
MXPA02011524A (es) 2004-09-10
US20040006241A1 (en) 2004-01-08
CA2409869C (en) 2009-02-03
BG65968B1 (bg) 2010-07-30
IL152868A (en) 2009-08-03
EA005623B1 (ru) 2005-04-28

Similar Documents

Publication Publication Date Title
ECSP084358A (es) NUEVAS FORMAS SÓLIDAS DE LA MESOPROGESTINA 11ß-[4E-(HIDROXIIMINOMETIL)-FENIL]- 17ALFA-METOXIMETIL-17ß-METOXI-ESTRA-4,9-DIEN-3-ONA
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
AR007827A1 (es) 3-ureido-piridofuranos y -piridotiofenos, procedimiento para su preparacion, composicion que los comprende y uso de dichos compuestos para lapreparacion de medicamentos.
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
IS6614A (is) Ný tríasólpýrimídínefnasambönd
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
BR9406979A (pt) Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
ECSP066500A (es) Pastas y varillas sólidas de fosfato de calcio inyectable para la liberación de proteínas osteogénicas
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
ATE386725T1 (de) Heterocyclylverbindungen
ECSP044973A (es) Nuevas formas polimorficas cristalinas de clorhidrato de lercanidipina y proceso para su preparacion
NO20032371L (no) Makrolidsolvater
SE0003476D0 (sv) Compounds
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva
ECSP10010159A (es) Ácido 4-[4-(2-adamantilcarbamoil)-5-tert-butilpirazol-1-il]benzoico - 465
AR035064A1 (es) 3-(1-metil-3-indolil)-4-(1-metil-6-nitro-3-indolil)-1h-pirrol-2,5-diona, en forma amorfa, procesos para prepararla, composicion farmaceutica que la comprende y uso de dicho compuesto en la fabricacion de medicamentos
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
PE20011080A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
AU2003267551A1 (en) Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
ECSP034604A (es) Inhibicion de la dependendia de celulas tumorales del factor de crecimiento
CO5261624A1 (es) Novedosos derivados fenilheteroalquilamina, procesos para su preparacion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia
PE20020511A1 (es) Uso de antiprogestinas para la induccion de apoptosis en una celula